Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].

Bulletin du cancer - 1 Sept 2006

Tonin Patricia N

Abstract excerpt

The unique genetic demography of the French Canadian population of Quebec, Canada, has provided a means to study the contribution of BRCA1 and BRCA2, the breast-ovarian cancer susceptibility genes. Here we review BRCA1 and BRCA2 in the context of French Canadian cancer families, a well-characterized founder population known for its contributions to medical genetics. Pathogenic BRCA1 and BRCA2 mutations contribute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Emigration and Immigration
Share to Family

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Founder Effect

Share to France

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Quebec

Source

Identifiers

PMID: 16980226

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].PMID 16980226Read ↗

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.Semantic proximity Read ↗

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.Semantic proximity Read ↗

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.Semantic proximity Read ↗

Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history.Semantic proximity Read ↗

Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.Semantic proximity Read ↗

The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.Semantic proximity Read ↗

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.Semantic proximity Read ↗

Germline TP53 mutational spectrum in French Canadians with breast cancer.Semantic proximity Read ↗

Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.Semantic proximity Read ↗

Hereditary breast cancer next-generation sequencing (NGS) panel evaluation in the south region of Brazil: a novel<i>BRCA2</i>candidate pathogenic variant is reportedSemantic proximity Read ↗

Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.Semantic proximity Read ↗

The genetic analysis of a founder Northern American population of European descent identifies<i>FANCI</i>as a candidate familial ovarian cancer risk geneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.